Please assess the completion status of the following clinical trial:

Trial Title: Tapering Off Antidepressants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently taking an FDA-approved antidepressant for at least four weeks on the list of approved medications: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vilazodone or vortioxetine), SNRIs (desvenlafaxine, duloxetine, levomilnacipran, venlafaxine) and other classes (amitriptyline, bupropion, desipramine, doxepin, mirtazapine, nefazodone, nortriptyline, phenelzine, selegiline, or tranylcypromine). Clomipramine, a tricyclic antidepressant approved for the treatment of OCD, will also be included, but will be classed as an SSRI for this study because inhibition of the serotonin transporter is its primary therapeutic mechanism.~* No longer wish to take the antidepressant medication they are currently prescribed, due to one of the following reasons: 1) ineffective for symptoms; 2) intolerable side effect; 3) improvement of their illness for sufficient duration that it is clinically appropriate to consider tapering the medication.~* Primary psychiatric diagnosis of major depressive disorder, an anxiety disorder, OCD, or PTSD.~* Ability to read and understand English language.~Exclusion Criteria:~* Has met criteria at any time during their life for a primary psychotic disorder (e.g. schizophrenia), or dementia.~* Meets criteria for DSM-5-defined substance use disorder within three months of the screening visit.~* Currently taking two or more antidepressants.~* Presents with a clinically significant suicide risk, as assessed by a study physician.~* Presence of any unstable or central nervous system-related medical illness that would interfere with cognition or participation.~* Women who are currently pregnant or lactating, or plan to become pregnant during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Taper A Regimen (Type: ACTIVE_COMPARATOR): Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
- Taper B Regimen (Type: ACTIVE_COMPARATOR): Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).